Teva Pharma (TEVA) and MODAG Collaborate on Neurodegenerative Disease Drug Candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teva Pharma (TEVA) Intends to Issue $4B Offering of Sustainability-linked Senior Notes
October 27, 2021 7:16 AM EDTTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today its intention to issue $4,000,000,000 of sustainability-linked senior notes. The notes offering reflects Tevas strong environmental, social and governance (ESG) commitment to some of the greatest challenges of our time by setting novel ambitious targets to increase access to medicines in low and middle-income countries by 150%, and new ambitious climate action targets, including a 25% reduction of Scope 1 and 2 greenhouse emissions by 2025 in alignment with the Paris Climate Agreement.
This sustainability-linked financing framework was validated by two Second Party Opinions (SPO), which were provided by... More
Teva Pharma (TEVA) Misses Q3 EPS by 6c
October 27, 2021 7:04 AM EDTTeva Pharma (NYSE: TEVA) reported Q3 EPS of $0.59, $0.06 worse than the analyst estimate of $0.65. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $4.03 billion.
GUIDANCE:
Teva Pharma reaffirms FY2021 EPS of $2.50-$2.70 and revenue of... More
